남미의 당뇨병약 : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the South America diabetes drugs market is expected to grow from USD 3.91 billion in 2025 to USD 4.04 billion in 2026, and is forecasted to reach USD 4.93 billion by 2031, at a CAGR of 4.08% during 2026-2031.

South America Diabetes Drugs Market Trends and Insights

Rising Type 2 Diabetes and Obesity Burden

Rising diabetes and obesity create the broadest demand base for the South American diabetes drugs market. PAHO reported in 2025 that diabetes cases in the Americas had increased 53.6% since 2000. The same report placed physical inactivity at 35.6%, the highest regional level globally. These factors extend the pool of people likely to require long-term glucose management. The region's urban population exceeds 83%, concentrating dietary and lifestyle risks in large population centers. The IDF estimated diabetes-related health expenditure at USD 81 billion in South and Central America during 2024.

Type 2 diabetes accounts for most of this treatment need because it is closely linked with obesity and inactivity. Prevention measures can slow new cases, but they do not remove the ongoing medication needs of diagnosed patients. This gives the South American diabetes drugs market a durable base even when reimbursement is uneven across public and private health systems.

Broader Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors

GLP-1 receptor agonists and SGLT2 inhibitors are changing prescribing patterns within the South American diabetes drugs market. Their use has expanded beyond basic glucose control because clinicians also consider cardiovascular, renal, and weight-related outcomes. Brazil added dapagliflozin, marketed as Forxiga, to the Farmacia Popular program in February 2025.This improved subsidized access for eligible patients and gave the class a clearer place in the public access system.

Local production could determine how widely these therapies and insulin products reach patients. Brazil resumed domestic insulin production in 2025 after a 20-year gap through a Ministry of Health-led initiative. Domestic supply can reduce exposure to import disruptions and strengthen public procurement planning. The South American diabetes drugs market may therefore gain volume through lower-cost alternatives while innovators compete on new formulations and evidence.

High Out-of-Pocket Spending and Uneven Reimbursement

High personal costs and incomplete coverage restrict the reach of the South American diabetes drugs market. FIFARMA reported that patients in South America waited an average of 4.75 years for innovative therapies to receive limited or full public availability after FDA or EMA approval. Colombia and Chile recorded waiting periods exceeding 5 years. This delay limits access to new therapies even after they are available for sale. Patients without generous private coverage may remain on older, less expensive products. Price reductions from local alternatives can expand access, but they do not fully address public coverage gaps.

The difference between public and private treatment pathways can widen access disparities. PAHO has stated that 43 million people with diabetes in the Americas cannot access treatment. National health agencies use separate evidence reviews, budgets, and formulary rules. The South American diabetes drugs market, therefore, remains constrained by affordability despite rising clinical interest in newer treatments.

Other drivers and restraints analyzed in the detailed report include:

1. Government Subsidies and Essential-Medicine Programs
2. Digital Prescribing, Tele-pharmacy, and Adherence Support
3. Rural Cold-Chain and Last-Mile Availability Gaps

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Insulin drugs held 39.51% of the South American diabetes drugs market in 2025, supported by their essential role in type 1 diabetes and extensive use in type 2 diabetes. Public procurement remains important because insulin is supplied through hospitals, primary care networks, and national programs. Domestic production could improve supply resilience and reinforce insulin's established role. The scale of public tenders makes reliable supply and competitive pricing important for suppliers.

Combination drugs are projected to achieve the highest growth rate at a 5.24% CAGR through 2031. Fixed-dose products that pair SGLT2 inhibitors with metformin or DPP-4 inhibitors can simplify daily treatment. This supports patients who need more than one mechanism of action but prefer fewer tablets. GLP-1 receptor agonists are strengthening the non-insulin injectable group, although access remains more limited than for conventional medicines. The South American diabetes drugs industry is thus balancing a large, procurement-led insulin base with faster growth in therapies designed around adherence and combination care.

Type 2 diabetes accounted for 89.42% of the South American diabetes drugs market in 2025 and is forecasted to grow at a 6.35% CAGR through 2031. This position reflects the region's disease burden and the use of higher-value GLP-1 and SGLT2 therapies in type 2 care. Patients may move from lifestyle treatment to oral monotherapy, multiple oral therapies, and injectable products over time. This progression creates demand across several drug classes. Younger presentation of type 2 diabetes also extends the period during which patients may require treatment.

Type 1 diabetes represents a smaller share but remains strategically important to insulin demand. Patients in this group depend on consistent access to rapid-acting, basal, and long-acting insulin formulations. The 2024 SUS expansion of analog insulin access to type 2 patients brings the two treatment populations closer within public formulary planning. Argentina's 2025 bioequivalence requirements for new oral hypoglycemic active ingredients add a regulatory step for generic oral products. The South American diabetes drugs market must therefore serve a high-volume type 2 population without weakening essential type 1 supply infrastructure.

Complete Report Scope:

• By Drug Class
  • Insulin Drugs
    • Traditional Human Insulin
    • Basal or Long-Acting Insulin
    • Insulin Combinations
    • Other Insulin Drugs
  • Oral Anti-Diabetes Drugs
    • Biguanides
    • SGLT2 Inhibitors
    • DPP-4 Inhibitors
    • Other Oral Anti-Diabetes Drugs
  • Non-Insulin Injectable Drugs
    • GLP-1 Receptor Agonists
    • Amylin Analogs
  • Combination Drugs
• By Diabetes Type
  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes
• By Route of Administration
  • Oral
  • Subcutaneous
  • Intravenous
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other Distribution Channels
• By Country
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America

List of Companies Covered in this Report:

1. Astellas Pharma
2. AstraZeneca
3. Biocon
4. Biomm S.A.
5. Boehringer Ingelheim
6. Boehringer Ingelheim and Eli Lilly Alliance
7. Bristol-Myers Squibb
8. Eli Lilly and Company
9. EMS S.A.
10. Eurofarma Laboratorios S.A.
11. Glenmark Pharmaceuticals
12. Hypera S.A.
13. Janssen
14. Merck
15. Novartis
16. Novo Nordisk
17. Pfizer
18. Sanofi
19. Takeda Pharmaceuticals
20. Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Type 2 Diabetes and Obesity Burden
  • 4.2.2 Broader Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors
  • 4.2.3 Government Subsidies and Essential-Medicine Programs
  • 4.2.4 Increasing Diagnosis, Screening, and Treatment Initiation
  • 4.2.5 Local Insulin and Peptide Manufacturing
  • 4.2.6 Digital Prescribing, Tele-pharmacy, and Adherence Support
• 4.3 Market Restraints
  • 4.3.1 High Out-of-Pocket Spending and Uneven Reimbursement
  • 4.3.2 Fragmented Formularies and Slow HTA-Based Coverage Expansion
  • 4.3.3 Rural Cold-Chain and Last-Mile Availability Gaps
  • 4.3.4 Protocol-Driven Switching and Discontinuity in Public Programs
• 4.4 Supply Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Drug Class
  • 5.1.1 Insulin Drugs
    • 5.1.1.1 Traditional Human Insulin
    • 5.1.1.2 Basal or Long-Acting Insulin
    • 5.1.1.3 Insulin Combinations
    • 5.1.1.4 Other Insulin Drugs
  • 5.1.2 Oral Anti-Diabetes Drugs
    • 5.1.2.1 Biguanides
    • 5.1.2.2 SGLT2 Inhibitors
    • 5.1.2.3 DPP-4 Inhibitors
    • 5.1.2.4 Other Oral Anti-Diabetes Drugs
  • 5.1.3 Non-Insulin Injectable Drugs
    • 5.1.3.1 GLP-1 Receptor Agonists
    • 5.1.3.2 Amylin Analogs
  • 5.1.4 Combination Drugs
• 5.2 By Diabetes Type
  • 5.2.1 Type 1 Diabetes
  • 5.2.2 Type 2 Diabetes
  • 5.2.3 Gestational Diabetes
• 5.3 By Route of Administration
  • 5.3.1 Oral
  • 5.3.2 Subcutaneous
  • 5.3.3 Intravenous
• 5.4 By Distribution Channel
  • 5.4.1 Hospital Pharmacies
  • 5.4.2 Retail Pharmacies
  • 5.4.3 Online Pharmacies
  • 5.4.4 Other Distribution Channels
• 5.5 By Country
  • 5.5.1 Brazil
  • 5.5.2 Argentina
  • 5.5.3 Colombia
  • 5.5.4 Chile
  • 5.5.5 Peru
  • 5.5.6 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, Recent Developments)
  • 6.3.1 Astellas Pharma Inc.
  • 6.3.2 AstraZeneca
  • 6.3.3 Biocon Limited
  • 6.3.4 Biomm S.A.
  • 6.3.5 Boehringer Ingelheim
  • 6.3.6 Boehringer Ingelheim and Eli Lilly Alliance
  • 6.3.7 Bristol Myers Squibb
  • 6.3.8 Eli Lilly and Company
  • 6.3.9 EMS S.A.
  • 6.3.10 Eurofarma Laboratorios S.A.
  • 6.3.11 Glenmark Pharmaceuticals Limited
  • 6.3.12 Hypera S.A.
  • 6.3.13 Janssen Pharmaceuticals
  • 6.3.14 Merck and Co., Inc.
  • 6.3.15 Novartis AG
  • 6.3.16 Novo Nordisk
  • 6.3.17 Pfizer Inc.
  • 6.3.18 Sanofi
  • 6.3.19 Takeda Pharmaceutical Company Limited
  • 6.3.20 Viatris Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment